Inhibition of the NLRP3 inflammasome may also be beneficial in other diseases, such as sickle anemia, β‐thalassemia, plasmodium infection, and rhabdomyolysis, which produce many hemes. Here, NLRP3 is linked to rhabdomyolysis.